Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP)
NCT ID: NCT05579301
Last Updated: 2022-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
130 participants
OBSERVATIONAL
2021-12-19
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy)
NCT04691635
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
NCT04753320
Biomarkers in Parkinsonian Syndromes
NCT02114242
Risk Factors for Progressive Supranuclear Palsy (PSP)
NCT00431301
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
NCT06490926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PSP patients
Patients with PSP according to the inclusion and exclusion criteria
No interventions assigned to this group
healthy controls
age-matched healthy controls according to the inclusion and exclusion criteria
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Progressive supranuclear palsy (PSP) patients who are diagnosed as Probable, Possible or suggestive PSP with Movement Disorder society diagnostic criteria for PSP (Hoglinger et al., 2017)
* Age 50 to 80 years, male or female
* Those who agreed to participate in this study
Exclusion Criteria
* Subjects with cancer or severe medical illness
* Lactating, pregnant, or possibly pregnant
* Subjects with small vessel disease (\> grade II) in brain MRI or other structural lesions by causes other than PSP
* Subjects with severe dementia patients (MMSE \< 19 or MoCA \<13 or General deterioration scale \>= 5)
* Those with a history of any neurological diseases
* Lactating, pregnant, or possibly pregnant
* Subjects with clinically significant psychiatric illness
* Subjects with cancer or severe medical illness
50 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SMG-SNU Boramae Medical Center
OTHER
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jee-Young Lee
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jee-Young Lee, M.D.
Role: PRINCIPAL_INVESTIGATOR
SMG-SNU Boramae Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Boramae Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNUH_2022_0117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.